Kidney Transplant – Current Treatment – Detailed, Expanded Analysis (US)
Each year in the United States, thousands of patients suffering from end-stage renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. However, these powerful agents come with considerable risks on top of their important benefits. This report explores the differences in prescribing practices, attitudes, and perceptions of the general nephrologists, transplant nephrologists, and transplant surgeons involved in kidney patients’ continuum of care and uncovers potential opportunities in the marketing of current and future immunosuppressant therapies.
QUESTIONS ANSWERED
What are the key drug classes used for induction and maintenance immunosuppressive regimens in kidney transplant patients?
How do prescribers adjust induction and maintenance regimens if patients are not responding adequately?
What are the key drivers and constraints of prescribing the most popular branded agents?
What are prescribers’ estimates regarding patients’ compliance with current therapies?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Kidney Transplant - Current Treatment - Detailed, Expanded Analysis (US)
Current Treatment Physician Insights Kidney Transplant US May 2019
Tim Blackstock, M.B., Ch.B., M.Phil.
Tim Blackstock, M.B. Ch.B., M.Phil., is a senior director on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored numerous reports focusing on metabolic indications, chiefly dyslipidemia, obesity, and nonalcoholic steatohepatitis (NASH), and has expertise in renal disorders and hemophilia. He has collaborated extensively with Clarivate’s Real World Data and Analytics team to provide expert analysis and advice, particularly related to NASH projects. Previously, Dr. Blackstock worked in the medical communications industry, providing scientific writing and editorial assistance to leading pharmaceutical companies in a variety of therapeutic areas. He holds bachelor degrees in medicine and surgery from the University of Otago in New Zealand and practiced medicine for five years, rotating through various specialties, including internal medicine, general surgery, and psychiatry.
